Study of IBI363 vs pembrolizumab for advanced mucosal or acral melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug, IBI363, compared to the standard drug pembrolizumab (Keytruda) for people with advanced mucosal or acral melanoma who have not had treatment before. It aims to see if IBI363 works better or as well as the usual treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of melanoma called mucosal or acral melanoma that has spread and cannot be removed by surgery.
- You have not had any previous cancer treatment for this advanced stage (like immunotherapy or targeted therapy).
- You have at least one tumor that can be measured on a CT or MRI scan.
- Your daily activities are not limited by your health (score 0 or 1 on a standard scale).
- Your doctor expects you to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called IBI363 for people with advanced melanoma that has progressed after standard treatment. It aims to see if IBI363 can shrink tumors or slow their growth.
This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.
This trial tests a combination of three immunotherapy drugs (cemiplimab, fianlimab, and ipilimumab) before surgery in people with melanoma that can be surgically removed. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.